CNP 103
Alternative Names: CNP-103; CNP-T1DLatest Information Update: 12 Feb 2025
At a glance
- Originator Cour Pharmaceutical Development
- Class Antihyperglycaemics; Polymers; Proteins
- Mechanism of Action Immunomodulators; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Type 1 diabetes mellitus
Most Recent Events
- 04 Feb 2025 The US FDA has cleared IND application for CNP 103 for Type 1 diabetes mellitus
- 04 Feb 2025 Cour Pharmaceutical Development plans a phase I/II trial for type 1 diabetes mellitus (In adults, In children, Late-stage disease, Newly diagnosed) in April 2025 (NCT06783309)
- 29 Jan 2025 Preclinical development in Type-1 diabetes mellitus is still on going (Cour Pharmaceutical Development pipeline, January 2025)